Morepen Laboratories Limited (MOREPENLAB.BO)
INR 49.26
(3.05%)
INR 49.26
(3.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.17 Billion INR | 158.26% |
| 2022 | 484.61 Million INR | -61.4% |
| 2021 | 1.25 Billion INR | 35.83% |
| 2020 | 924.26 Million INR | 374.47% |
| 2019 | 194.8 Million INR | 16.79% |
| 2018 | 166.79 Million INR | -26.3% |
| 2017 | 226.32 Million INR | 15.03% |
| 2016 | 196.75 Million INR | 95.73% |
| 2015 | 100.52 Million INR | -8.09% |
| 2014 | 109.37 Million INR | 155.54% |
| 2013 | 42.8 Million INR | 135.73% |
| 2012 | -119.8 Million INR | 56.69% |
| 2011 | -276.6 Million INR | 33.11% |
| 2010 | -413.5 Million INR | -13.18% |
| 2009 | -365.33 Million INR | 22.81% |
| 2008 | -473.31 Million INR | 18.0% |
| 2007 | -577.24 Million INR | -36.38% |
| 2006 | -423.27 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 458.91 Million INR | 115.66% |
| 2023 Q1 | 183.74 Million INR | 114.16% |
| 2023 FY | 1.25 Billion INR | 158.26% |
| 2023 Q4 | 387.56 Million INR | -7.99% |
| 2023 Q3 | 421.21 Million INR | 62.61% |
| 2023 Q2 | 259.02 Million INR | 40.97% |
| 2022 Q3 | 133.27 Million INR | -39.16% |
| 2022 Q1 | 77.88 Million INR | -33.95% |
| 2022 Q2 | 219.06 Million INR | 181.27% |
| 2022 FY | 484.61 Million INR | -61.4% |
| 2022 Q4 | 85.79 Million INR | -35.62% |
| 2021 FY | 1.25 Billion INR | 35.83% |
| 2021 Q3 | 251.93 Million INR | -27.78% |
| 2021 Q4 | 117.92 Million INR | -53.19% |
| 2021 Q1 | 371.58 Million INR | 185.32% |
| 2021 Q2 | 348.85 Million INR | -6.12% |
| 2020 Q2 | 278.09 Million INR | 40.15% |
| 2020 FY | 924.26 Million INR | 374.47% |
| 2020 Q1 | 198.42 Million INR | 72.61% |
| 2020 Q4 | 130.23 Million INR | -48.04% |
| 2020 Q3 | 250.66 Million INR | -9.86% |
| 2019 FY | 194.8 Million INR | 16.79% |
| 2019 Q1 | 81.08 Million INR | -27.17% |
| 2019 Q2 | 96.29 Million INR | 18.77% |
| 2019 Q3 | 113.69 Million INR | 18.06% |
| 2019 Q4 | 114.95 Million INR | 1.11% |
| 2018 Q3 | 94.63 Million INR | 33.24% |
| 2018 FY | 166.79 Million INR | -26.3% |
| 2018 Q2 | 71.02 Million INR | 129.74% |
| 2018 Q4 | 111.32 Million INR | 17.63% |
| 2018 Q1 | 30.91 Million INR | -57.51% |
| 2017 Q3 | 113.54 Million INR | -8.39% |
| 2017 Q4 | 72.76 Million INR | -35.92% |
| 2017 FY | 226.32 Million INR | 15.03% |
| 2017 Q1 | 25.99 Million INR | 0.0% |
| 2017 Q2 | 123.94 Million INR | 376.73% |
| 2016 FY | 196.75 Million INR | 95.73% |
| 2015 FY | 100.52 Million INR | -8.09% |
| 2014 FY | 109.37 Million INR | 155.54% |
| 2013 FY | 42.8 Million INR | 135.73% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | -119.8 Million INR | 56.69% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2011 FY | -276.6 Million INR | 33.11% |
| 2010 FY | -413.5 Million INR | -13.18% |
| 2009 FY | -365.33 Million INR | 22.81% |
| 2008 FY | -473.31 Million INR | 18.0% |
| 2007 FY | -577.24 Million INR | -36.38% |
| 2006 FY | -423.27 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 27.514% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 90.11% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 53.517% |
| Granules India Limited | 6.81 Billion INR | 38.771% |
| Indoco Remedies Limited | 1.29 Billion INR | -222.915% |
| Achyut Healthcare Limited | 4.43 Million INR | -93947.566% |
| Ajanta Pharma Limited | 19.67 Billion INR | 78.789% |
| Alkem Laboratories Limited | 19.46 Billion INR | 78.554% |
| Alpa Laboratories Limited | 184.49 Million INR | -2162.276% |
| Brooks Laboratories Limited | 14.44 Million INR | -28804.647% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -143.018% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -239.06% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 93.837% |
| Eris Lifesciences Limited | 5.18 Billion INR | 19.451% |
| FDC Limited | 2.98 Billion INR | -39.77% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 35.811% |
| Gufic Biosciences Limited | 1.32 Billion INR | -213.843% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 5.581% |
| Ipca Laboratories Limited | 7.98 Billion INR | 47.7% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -721.41% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 2846.718% |
| Lasa Supergenerics Limited | -458 Million INR | 1011.307% |
| Laurus Labs Limited | 3.94 Billion INR | -5.704% |
| Lupin Limited | 28.04 Billion INR | 85.117% |
| Mankind Pharma Limited | 21.51 Billion INR | 80.603% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -4061.347% |
| Megasoft Limited | -121.1 Million INR | 3546.485% |
| NATCO Pharma Limited | 25.96 Billion INR | 83.923% |
| Piramal Pharma Limited | 4.55 Billion INR | 8.406% |
| RPG Life Sciences Limited | 2.29 Billion INR | -82.08% |
| Sigachi Industries Limited | 1.47 Billion INR | -183.184% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 95.998% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 9.415% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1574.549% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -632.616% |
| Windlas Biotech Limited | 1.29 Billion INR | -221.338% |
| ZIM Laboratories Limited | 253.82 Million INR | -1544.348% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 90.318% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 201.429% |
| Divi's Laboratories Limited | 33.08 Billion INR | 87.383% |
| Hester Biosciences Limited | 364.81 Million INR | -1044.111% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -49.814% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -812.225% |
| Bal Pharma Limited | 233.9 Million INR | -1684.382% |
| Strides Pharma Science Limited | 5.22 Billion INR | 20.13% |
| Venus Remedies Limited | 534.65 Million INR | -680.665% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -33.43% |
| Nectar Lifesciences Limited | 923.8 Million INR | -351.808% |
| Shilpa Medicare Limited | 1.36 Billion INR | -205.49% |
| Aarti Drugs Limited | 7.14 Billion INR | 41.614% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -161.387% |
| Suven Life Sciences Limited | -1.22 Billion INR | 440.492% |
| Ind-Swift Limited | 1.22 Billion INR | -240.453% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 70.777% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 208.33% |
| Themis Medicare Limited | 392.58 Million INR | -963.155% |
| Hikal Limited | 32.11 Million INR | -12898.539% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 83.526% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -566.214% |
| Wockhardt Limited | -670 Million INR | 722.96% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 19.564% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -45924.579% |
| Neuland Laboratories Limited | 5.31 Billion INR | 21.516% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1906.167% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -15100.783% |